electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
March 23, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a paper...
electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study
March 21, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a...
electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank
March 14, 2023 08:30 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it does not have direct exposure...
electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
March 13, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that data from a sham controlled...
electroCore to Participate at 35th Annual Roth Conference
March 09, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, March 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s...
electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023 16:05 ET
|
electroCore, Inc.
Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J.,...
electroCore Regains Compliance with Nasdaq Listing Requirements
March 07, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received notice from...
electroCore to Announce Fourth Quarter and Year Ended December 31, 2022 Financial Results on Wednesday, March 8
March 01, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial...
electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa
February 21, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with...
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
February 16, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and...